A PHASE 1B MULTICENTER, OPEN-LABEL STUDY TO DETERMINE THE RECOMMENDED DOSE AND REGIMEN OF DURVALUMAB (MEDI4736) EITHER AS MONOTHERAPY OR IN COMBINATION WITH POMALIDOMIDE (POM) WITH OR WITHOUT LOWDOSE DEXAMETHASONE (DEX) IN SUBJECTS WITH RELAPSED AND REFRACTORY MULTIPLE MYELOMA (RRMM)

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MM-001

To Learn More Call
201-510-0910